Clinical Trial Update: Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE) [Phase 2]

View source ↗

Summary

Phase 2 trial (E-VIRTUE) evaluating enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors is currently recruiting, including bladder ade…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Bladder
• Squamous Cell Carcinoma of the Bladder
• Testicular Germ Cell Tumor

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Padcev (enfortumab vedotin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Bladder, Squamous Cell Carcinoma of the Bladder | Phase 2 | Status: RECRUITING